Activity OverviewThe ACR’s State-of-the-Art Clinical Symposium (SOTA) includes lectures from key opinion leaders, plus a Q&A session for each. The lectures encompass a variety of topics, including new therapies and indications in rheumatic disease treatment, large vessel vasculitis, pregnancy and reproductive health, and lupus in diverse skin types.The activity includes the following sessions:Rheumatic Disease TreatmentBiosimilars in RheumatologyLarge Vessel Vasculitis ImagingNew Concepts in Relapsing PolychondritisDeciphering IgG4-Related DiseaseDemystifying Pain and Fatigue in LupusLupus in Color: Cutaneous Lupus in Diverse Skin TypesPregnancy and Reproductive Health in RheumatologyUnraveling Hypermobility DisordersIdiopathic Inflammatory Myopathy-Associated Cancer Screening UpdatesRegistration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.ACR/ARP Member: $399ACR/ARP Potential Member: $599Target AudienceRheumatologists (physicians) in clinical care and/or research, fellows in training, division directors, program directors, assistant program directors, physician assistants, nurse practitioners, pharmacists, nurses, and epidemiologists.Learning ObjectivesUpon completion of this activity, participants should be able to:Recognize and differentiate the clinical presentations and phenotypes of patients with complex rheumatic diseases, including relapsing polychondritis, IgG4-related disease, and hypermobility syndromes, to enhance diagnostic accuracy and individualized patient careDiscuss the most up-to-date evidence-based treatment approaches, including novel therapies, in the management of a variety of rheumatic diseases, including relapsing polychondritis, osteoporosis, and spondyloarthritisDiscuss and implement current recommendations regarding pregnancy and reproductive health issues pertinent to women and men with rheumatic diseaseSummarize and apply guidelines for cancer screening in myositis, with a focus on identifying specific subtypes that necessitate more intensive monitoring, to enhance early detection and improve patient outcomes in this vulnerable populationCE and MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.AMA Designation StatementThe American College of Rheumatology designates this Enduring Material for a maximum of 7.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by May 1, 2028, at 11:59 PM ET.MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM)Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board. After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.MOC points must be claimed by May 1, 2028, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify detailsNone: Has no relevant financial relationship(s) with ineligible companies to disclose.All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. State-of-the-Art Clinical Symposium 2025 Financial Relationship Disclosures.Acknowledgement of Commercial SupportNo commercial support was provided for this activity.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.